The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

Hennepin Healthcare

Status and phase: Completed; Phase 4

Conditions: Brain Injury; Venous Thrombosis

Treatments: Drug: Enoxaparin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00170378

HSR #02-2113

Details and patient eligibility

About

To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.

Full description

Venous thromboembolic (VTE) prophylaxis in trauma patients is a critical clinical problem. Patients with traumatic brain injury usually have effective VTE prophylaxis withheld secondary to concerns of exacerbating intracranial hemorrhage. This study examines the safety and efficacy of early administration (within 24 hrs of admission) of low molecular weight heparin to this patient population with very high VTE risk.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Blunt traumatic brain injury (Marshall II-V)
• Stable 6 hr. head CT
• Stable hemoglobin

Exclusion criteria

• Premorbid coagulopathy
• Pregnancy
• < 18 y.o.
• Need for therapeutic anticoagulation
• Heparin allergy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind